Novartis on goal to hit mid-30s margins by 2022

Novartis is on track to achieve profit margins in the mid-30s, plans to spend about 5% of market cap per year on M&A and business development and licensing, and will complete a $5 billion share buyback

Read the full 369 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE